Institutional Investor Sentiment About Celgene Corp (NASDAQ:CELG) Up

Celgene Corporation (NASDAQ:CELG) Logo

Sentiment for Celgene Corp (NASDAQ:CELG)

Celgene Corp (NASDAQ:CELG) institutional sentiment decreased to 0.55 in 2019 Q2. Its down -0.21, from 0.76 in 2019Q1. The ratio has worsened, as 299 funds opened new and increased equity positions, while 540 cut down and sold their positions in Celgene Corp. The funds in our partner’s database reported: 466.35 million shares, down from 482.72 million shares in 2019Q1. Also, the number of funds holding Celgene Corp in their top 10 equity positions was flat from 63 to 63 for the same number . Sold All: 97 Reduced: 443 Increased: 216 New Position: 83.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $69.74 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 13.45 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

The stock decreased 0.23% or $0.23 during the last trading session, reaching $98.4. About 2.75 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 3.32% since September 13, 2018 and is uptrending. It has outperformed by 3.32% the S&P500.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on October, 24. They expect $2.58 earnings per share, up 27.09 % or $0.55 from last year’s $2.03 per share. CELG’s profit will be $1.83B for 9.53 P/E if the $2.58 EPS becomes a reality. After $2.61 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -1.15 % negative EPS growth.

Birchview Capital Lp holds 39.22% of its portfolio in Celgene Corporation for 697,667 shares. Burren Capital Advisors Ltd owns 50,900 shares or 38.16% of their US portfolio. Moreover, Oaktop Capital Management Ii L.P. has 36.45% invested in the company for 1.83 million shares. The United Kingdom-based Boussard & Gavaudan Investment Management Llp has invested 32.11% in the stock. Abrams Capital Management L.P., a Massachusetts-based fund reported 6.75 million shares.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Ratings analysis reveals 50% of Celgene’s analysts are positive. Out of 2 Wall Street analysts rating Celgene, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $100 while the high is $103. The stock’s average target of $101.50 is 3.15% above today’s ($98.4) share price. CELG was included in 10 notes of analysts from March 26, 2019. Mizuho maintained the stock with “Buy” rating in Monday, June 24 report. Cantor Fitzgerald maintained the stock with “Hold” rating in Monday, June 24 report.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “Celgene (CELG) Gains But Lags Market: What You Should Know – Nasdaq” on September 05, 2019, also Finance.Yahoo.com with their article: “Why Amgen’s Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy – Yahoo Finance” published on September 06, 2019, Seekingalpha.com published: “Ligand Pharmaceuticals And The OmniAb Platform – Seeking Alpha” on September 06, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight – Benzinga” published on September 02, 2019 as well as Nasdaq.com‘s news article titled: “Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer – Nasdaq” with publication date: August 19, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.